BNF:

Immune system/malignant disease

Status:

Red

Decision Date:

January 2018

Comments

RED:

• NICE TA495 with aromatase inhibitor for previously untreated hormone receptor positive, HER2- negative, locally advanced or metastatic breast cancer.
• NICE TA619 - with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer. (Decision date - February 2020)
• NICE TA836 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. (Decision date - November 2022)

NHSE is the responsible commissioner. 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again